Voloridge Investment Management
ALXN

Voloridge Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Voloridge Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-220,520
Closed -$40.5M – 1986
2021
Q2 		$40.5M Buy
+220,520
New +$37.9M 0.28% 68
2021
Q1 		– Sell
-56,737
Closed -$8.87M – 1753
2020
Q4 		$8.87M Sell
56,737
-15,331
-21% -$1.97M 0.07% 300
2020
Q3 		$8.25M Sell
72,068
-10,381
-13% -$1.12M 0.07% 308
2020
Q2 		$9.25M Buy
+82,449
New +$8.75M 0.11% 214
2016
Q2 		– Sell
-67,302
Closed -$9.37M – 431
2016
Q1 		$9.37M Buy
+67,302
New +$9.88M 0.22% 98

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Voloridge Investment Management's ALXN Position: Q3 2021 in Review

Voloridge Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 220,520 shares — an estimated $40.5M sold.

Voloridge Investment Management first reported a position in ALXN in Q1 2016 and held it in 5 quarters. The position peaked at $40.5M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Voloridge Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Voloridge Investment Management sold 220,520 Alexion Pharmaceuticals shares in Q3 2021, an estimated $40.5M.
  • Voloridge Investment Management first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 5 quarters.
  • Voloridge Investment Management's Alexion Pharmaceuticals position peaked at $40.5M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Voloridge Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.